美国食品药物管理局(FDA)就20款ZYN尼古丁袋产品发出改良风险烟草产品(MRTP)授权令，允许菲利普莫里斯国际旗下美国子公司在行销时明确声称，这些产品引发口腔癌、心脏病、肺癌、中风、肺气肿及慢性支气管炎的风险均低于香烟。这是尼古丁袋产品首次获得此类监管认定。此次裁定对菲利普莫里斯国际具有重大商业意义，因为ZYN是其增长最快的消费品牌。
美国食品药物管理局(FDA)就20款ZYN尼古丁袋产品发出改良风险烟草产品(MRTP)授权令，允许菲利普莫里斯国际旗下美国子公司在行销时明确声称，这些产品引发口腔癌、心脏病、肺癌、中风、肺气肿及慢性支气管炎的风险均低于香烟。这是尼古丁袋产品首次获得此类监管认定。此次裁定对菲利普莫里斯国际具有重大商业意义，因为ZYN是其增长最快的消费品牌。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.